Antifection

Hitachimycin is a macrolide antibiotic known for its ability to inhibit tumor cell growth, showcasing significant antitumor activity. It also exhibits antiprotozoal effects, making it relevant for research in cancer therapy and protozoal infections. This compound can be utilized in various biomedical studies aimed at understanding tumorigenesis and potential treatment pathways.

Cefazedone sodium is a first-generation cephalosporin antibiotic targeting bacterial cell wall synthesis. It exhibits broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria. This compound is widely used in microbiological research to study bacterial resistance mechanisms and is essential for the development of new antimicrobial therapies.

Polymyxin D2 is an antibiotic derived from Bacillus polymyxa, demonstrating significant antibacterial activity. Its structure features a cyclic heptapeptide core and a tripeptide side chain with a fatty acyl group, contributing to its potent effects. This compound is valuable for research in anti-infective applications, providing insights into bacterial resistance mechanisms and therapeutic interventions.

Napsamycin C is an antibiotic that specifically targets Pseudomonas aeruginosa, exhibiting significant antibacterial activity against this organism and related Pseudomonas species. Its efficacy is notably reduced against other Gram-positive and Gram-negative bacteria, making it a valuable reagent for research focused on combating Pseudomonas infections. This compound is useful in studies of bacterial resistance and antibiotic efficacy.

Asparenomycin C is a carbapenem antibiotic that exhibits potent β-lactamase inhibition. This compound demonstrates significant antibacterial activity against a range of Gram-positive and Gram-negative bacteria, making it a valuable tool in studying antibiotic resistance mechanisms. It is utilized in research applications aimed at developing new antibiotics and understanding the interactions between β-lactam antibiotics and bacterial enzymes.

Altromycin B is an antibiotic that belongs to the pluramycin family, derived from South African bush soil. It exhibits selective antibacterial activity against Gram-positive bacteria and demonstrates in vivo efficacy against various cancers, including P388 leukemia, colon cancer, lung cancer, and ovarian cancer. This compound is valuable for research in antimicrobial resistance and cancer treatment studies.

Saquayamycin D is an antibiotic derived from the culture broth of Streptomyces nodosus. This compound demonstrates significant antibacterial activity against a range of gram-positive bacteria, exhibiting a minimum inhibitory concentration (MIC) of 12.5-50 μg/mL. Additionally, Saquayamycin D effectively inhibits the proliferation of both Doxorubicin-sensitive P388/S and Doxorubicin-resistant P388/ADR cell lines, with an IC50 of 0.15 μg/mL, making it valuable for cancer research applications.

Flambamycin is an antibiotic derived from the Streptomyces hygroscopicus DS 23230 strain, exhibiting activity against both Gram-positive and Gram-negative cocci, as well as certain Gram-positive rods. Its antimicrobial properties make it a valuable tool for research focused on antibiotic screening and the evaluation of novel antibacterial agents.

Gilvusmycin is an antitumor antibiotic that exhibits potent cytotoxic activity against various cancer cell lines. It effectively inhibits P388, K562, A431, and MKN28 cells, demonstrating IC50 values of 0.08, 0.86, 0.72, and 0.75 ng/mL, respectively. This compound is valuable for research applications in cancer biology and the development of novel anticancer therapies.

Mycoplanecin B is a cyclic peptide antibiotic known for its potent antibacterial activity. It selectively targets bacterial cell wall synthesis, inhibiting growth and proliferation of susceptible pathogens. This compound is primarily utilized in research applications focused on antimicrobial resistance and the development of novel antibiotic therapies.

O-Demethylpaulomycin A is an antibiotic that exhibits potent antibacterial activity, specifically targeting Gram-positive bacteria. This compound is particularly effective against Staphylococcus aureus, making it a valuable reagent for research applications focused on bacterial infections and antibiotic resistance. Its mechanism of action may provide insights into new therapeutic strategies for combating resistant bacterial strains.

Asparenomycin B is a carbapenem antibiotic that acts by inhibiting β-lactamase enzymes, thereby enhancing its efficacy against resistant bacterial strains. This compound exhibits robust antibacterial activity and is valuable for research applications focused on drug resistance mechanisms and antibiotic development. Its unique properties make it a significant tool for studies in microbiology and pharmacology.

Milbemycin α12 is an antibiotic that exerts its effects by targeting and disrupting the nervous systems of nematodes and mites. It is primarily utilized in research focused on parasitic infections and pest control. This compound demonstrates potent anthelmintic and acaricidal properties, making it valuable for studies related to parasitology and agricultural applications.

Oudenone is an oxygen-containing heterocyclic antibiotic that exhibits weak antibacterial and antifungal activities. It is also noted for its antihypertensive effects, demonstrating efficacy in reducing blood pressure in spontaneous hypertension models in rats via both intraperitoneal injection and oral administration. This compound may serve as a valuable tool in research focusing on antibiotic efficacy and hypertension management.

Cefpimizole is a broad-spectrum cephalosporin antibiotic that targets bacterial cell wall synthesis. It effectively inhibits a variety of ampicillin-resistant bacteria and demonstrates activity against gram-negative species. Additionally, Cefpimizole enhances the phagocytic activity of macrophages and neutrophils, making it valuable for studies in antimicrobial resistance and immune response modulation.

Pivampicillin hydrochloride is a penicillin antibiotic that acts as a prodrug for Ampicillin. This compound exhibits broad-spectrum antibacterial activity by targeting bacterial cell wall synthesis. It is utilized in research to investigate the mechanisms of antibiotic resistance and in the development of novel antibacterial therapies.

Methyl-6-gingerol is an antimicrobial compound primarily targeting bacterial efflux mechanisms. Isolated from Aframomum melegueta, it demonstrates significant anti-mycobacterial activity by inhibiting the efflux of toxins in Mycobacterium species. This property makes it a valuable reagent for research in antibiotic development and the study of mycobacterial resistance mechanisms.

Tiacumicin C is an antibiotic that effectively targets Gram-positive bacteria. It exhibits strong antibacterial properties, making it a valuable tool in research focused on bacterial infections and resistance mechanisms. Its unique structure and mechanism of action assist in the exploration of therapeutic strategies against resistant bacterial strains.

Sulopenem sodium is a parenteral penem antibiotic that exhibits broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria. This compound is particularly relevant for the treatment of urinary tract infections and intra-abdominal infections, offering a therapeutic option in complex infectious diseases. However, it is ineffective against Pseudomonas aeruginosa and Xanthomonas maltophilia.

Monamycin I is an ester peptide antibiotic known for its efficacy against Gram-positive bacteria. Its mechanism involves disrupting bacterial cell wall synthesis, thereby inhibiting growth. This compound is valuable for research into antibiotic resistance and the development of new antibacterial agents. Monamycin I provides a useful tool for studies focused on bacterial infection mechanisms and the evaluation of antibiotic susceptibility.

(Rac)-LY193239 is a racemic variant of LY193239, a higher-lactam pyrazolidinone with potent antibacterial properties. This compound demonstrates significant antimicrobial activity, making it a valuable tool for research into bacterial infections. Its mechanism as an antibacterial agent allows for investigations into therapeutic applications and the development of new antibiotics.

Mimosamycin is an antibiotic that exerts its activity primarily against mycobacteria and resistant strains of Streptomyces. Its mechanism of action involves inhibiting the growth of these microorganisms, making it a valuable reagent for research on antibiotic resistance and mycobacterial infections. This compound is essential for studies aiming to develop new therapeutic strategies and understand the underlying biology of resistant bacterial strains.

Roridin H is an antibiotic that targets bacterial ribosomes, inhibiting protein synthesis. Isolated from the fungus Myrothecium verrucaria, it exhibits significant antimicrobial activity against various pathogens. This compound is primarily utilized in research applications focusing on antibiotic resistance and microbial biochemistry.

Pyralomicin 1c is an antibiotic that exerts its antibacterial activity by targeting bacterial protein synthesis. It has demonstrated effectiveness against a range of Gram-positive bacteria, making it a valuable compound for the study of antibiotic mechanisms and resistance. Researchers can utilize Pyralomicin 1c in investigations aimed at developing new antimicrobial therapies and understanding bacterial pathogenesis.

Actithiazic acid is a nitrogen- and sulfur-containing antibiotic that exerts its effects primarily by targeting mycobacteria. This compound demonstrates significant antibacterial activity, making it useful for research focused on mycobacterial infections. Its mechanism of action and efficacy in combating resistant strains position it as a valuable reagent for the study of antibiotic resistance and potential therapeutic developments in infectious diseases.

Arylomycin B2 is a potent inhibitor of signal peptidase I (SPase I), functioning as an antibiotic in the treatment of bacterial infections. It exhibits significant anti-Gram-positive bacterial activity, making it a valuable reagent for research focused on bacterial protein secretion mechanisms and antibiotic development. Arylomycin B2 can be utilized in studies assessing bacterial resistance and the efficacy of novel antibiotic therapies.

Nebramycin IV is an aminoglycoside antibiotic that primarily targets bacterial protein synthesis by binding to the 30S ribosomal subunit. It exhibits a broad spectrum of antibacterial activity, effective against both Gram-positive and Gram-negative bacteria, as well as mycobacteria. This compound is primarily utilized in research applications focused on antimicrobial resistance and the mechanisms of bacterial infections.

Pyralomicin 1a is an antibiotic that targets bacterial cell wall synthesis. It exhibits strong antibacterial activity, making it a valuable reagent for research focused on bacterial infections and resistance mechanisms. This compound can be utilized in studies investigating the efficacy of novel antibiotics and the development of therapeutic strategies against multidrug-resistant pathogens.

Isosulfazecin is a novel β-lactam antibiotic with a unique mechanism of action targeting bacterial cell wall synthesis. Isolated from Pseudomonas acidophilus sp., it demonstrates significant antimicrobial activity against both gram-positive and gram-negative bacteria, particularly against strains resistant to traditional β-lactam antibiotics. Its structure features a β-lactam ring along with methoxyl and sulfonate groups, and it is effective in research applications focusing on antibiotic resistance and the development of new antimicrobial therapies.

10-Norparvulenone is an antibiotic exhibiting activity against influenza viruses and demonstrating antibacterial effects against Escherichia coli. This compound serves as a valuable reagent for research focused on antiviral and antibacterial pathways, aiding in the exploration of treatment strategies for infections caused by these pathogens. Its dual action makes it of interest for studies investigating multi-faceted antimicrobial therapies.

Norcyclizine is a piperazine derivative that primarily targets bacterial infections through its antibiotic properties. It has been shown to enhance the antibacterial efficacy of β-lactam antibiotics, such as oxacillin, against methicillin-resistant Staphylococcus aureus (MRSA) by inhibiting the allosteric site of PBP2a. Additionally, Norcyclizine serves as a valuable pharmacological scaffold for the development of novel anticancer agents, expanding its utility in medicinal chemistry research.

Leucomycin A9 is a macrolide antibiotic that primarily targets bacterial ribosomes to inhibit protein synthesis. It exhibits strong antibacterial activity against Gram-positive bacteria and is also effective against spirochetes, Rickettsia, and Chlamydia. This compound is valuable for research applications in studying bacterial resistance mechanisms and the efficacy of antibiotic therapies.

Pyralomicin 2c is an antibiotic that exhibits potent antibacterial activity by targeting bacterial cell wall synthesis. It is effective against a range of gram-positive bacteria, making it a valuable tool for studying bacterial infections and antibiotic resistance mechanisms. This compound is suitable for research applications focused on the development of new antimicrobial agents and understanding bacterial pathogenicity.

Lomofungin is a novel antibiotic derived from Streptomyces lomondensis sp. N, exhibiting potent antibacterial properties. It primarily functions by inhibiting the binding of MBNL1 to CUG RNA, which is significant in various biological processes. This compound is valuable for research applications focused on bacterial resistance mechanisms and the regulatory roles of RNA-binding proteins.

Seldomycin factor 2 is an aminoglycoside antibiotic that targets bacterial protein synthesis. It exhibits a broad spectrum of antimicrobial activity against various Gram-positive and Gram-negative pathogens. This compound is valuable for research into antibiotic resistance mechanisms and the development of new antimicrobial therapies.

Miyakamide B2 is an antitumor antibiotic known for its insecticidal properties. It effectively inhibits the growth of Artemia salina and exhibits modest activity against Xanthomonas spp. In vitro studies demonstrate that Miyakamide B2 inhibits P388 leukemia cells, with an IC50 value of 7.6 μg/mL. This compound is valuable for research in cancer biology and antibiotic efficacy.

Decatromicin A is a potent antibiotic derived from Actinomadura MK73-NF4, exhibiting significant activity against gram-positive bacteria. Its primary mechanism involves inhibiting bacterial growth, making it a valuable tool for research into antibiotic resistance and the development of new antimicrobial strategies. Decatromicin A is particularly useful in studies focused on bacterial infections and the mechanisms of antibiotic action.

Neospiramycin I is a macrolide antibiotic that targets bacterial ribosomes, inhibiting protein synthesis. It demonstrates significant antibacterial activity against macrolide-sensitive strains of Staphylococcus aureus, with a minimum inhibitory concentration (MIC) of 3.12 µg/mL, and exhibits effectiveness against various Gram-positive bacteria, including Bacillus cereus and Bacillus subtilis, along with Gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae, at MIC values ranging from 0.2 to 50 µg/mL. In vivo, Neospiramycin I protects mice in a type III S. pneumoniae infection model, with an effective dose 50 (ED50) of 399.8 mg/kg, making it a valuable tool for studies on bacterial resistance and antibiotic efficacy.

Phenelfamycin B is an antibiotic known for its anti-eutrophic bacterial activity. This compound effectively inhibits the growth of specific bacterial strains, making it valuable in research focused on antibiotic resistance and the development of new antibacterial agents. Its unique mechanism of action positions it as a useful tool for studying bacterial inhibition in various biological assays.

4'-O-Demethyldianemycin is a polyether antibiotic isolated from Streptomyces hygroscopicus TM-531. It exhibits potent activity against Gram-positive bacteria, making it a valuable tool for studying antibiotic efficacy and resistance mechanisms in relevant microbial populations. This compound is suitable for research applications involving bacterial infections and the development of new antimicrobial agents.

Aldecalmycin is an antibiotic that exerts its effect primarily against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It demonstrates strong antimicrobial activity, with minimum inhibitory concentration (MIC) values ranging from 6.25 to 25 μg/mL. This compound is useful in research applications aimed at understanding resistance mechanisms and developing novel antibacterial strategies.

MM 42842 free acid is a monobactam antibiotic that targets bacterial cell wall synthesis. It inhibits the activity of penicillin-binding proteins, disrupting the formation of peptidoglycan in bacterial cell walls. This compound exhibits potent antibacterial activity against Gram-negative bacteria and is primarily used in research applications related to antibiotic resistance and bacterial pathogen studies.

Diolmycin A1 is an antibiotic that exhibits potent anticoccidial activity. It is primarily used in research to investigate its efficacy against coccidial infections in various animal models. This compound is of particular interest for studies focused on the treatment and prevention of coccidiosis, providing insights into its pharmacological mechanisms and potential therapeutic applications.

GSK1829820A is an antibiotic with potent antitubercular activity, specifically targeting Mycobacterium tuberculosis H37Rv. This compound exhibits inhibitory effects on the growth of the bacteria, making it a valuable tool for research focused on tuberculosis treatment and drug development. Its efficacy provides a foundation for studying mechanisms of resistance and developing new therapeutic strategies against infectious diseases.

Napsamycin A is an antibiotic that primarily exhibits antibacterial activity against Pseudomonas aeruginosa and other Pseudomonas species. Its efficacy is limited against a range of Gram-positive and other Gram-negative bacteria. This compound is valuable for research applications focused on bacterial infections and the study of antibiotic resistance mechanisms.

Dactylocycline B is an antibiotic that exhibits potent activity against gram-positive bacteria, including strains resistant to tetracycline. Its unique mode of action interferes with bacterial protein synthesis, making it a valuable tool in studying antibiotic resistance and bacterial pathogenesis. Dactylocycline B may also aid in the development of novel therapeutic strategies against challenging bacterial infections.

Inosamycin A is a broad-spectrum antibiotic that functions by inhibiting bacterial protein synthesis. It exhibits significant antibacterial activity against a variety of gram-positive and gram-negative pathogens. This compound is valuable for research applications in microbial resistance studies and the development of novel antimicrobial therapies.

Auramycin B is an anthracycline antibiotic primarily targeting Gram-positive bacteria. It demonstrates significant antibacterial activity and has also been shown to exhibit antitumor effects against P388 and L1210 leukemia cell lines in murine models. This compound is valuable for research applications focused on antibiotic efficacy and cancer therapeutics.

PKZ18 is an antibiotic that specifically targets glycyl-tRNA synthetase mRNA, inhibiting both transcription and translation in bacterial cells. It demonstrates potent antibacterial activity against Gram-positive bacteria, with minimum inhibitory concentration (MIC) values ranging from 32 to 64 μg/mL. By selectively binding to stem I specifier loops, PKZ18 effectively reduces T-box transcriptional read-through of related genes, thus disrupting the essential codon-anticodon interaction necessary for tRNA binding. This mechanism also enhances its robustness against resistance development.

Granaticin methyl ester is a quinone antibiotic targeting bacterial cell viability. This compound exhibits significant antibacterial activity against both Gram-positive and Gram-negative bacteria, making it a valuable tool in microbiological research. Its efficacy in combating bacterial infections highlights its potential for further exploration in therapeutic applications.